Ex Parte KRIEGER - Page 8



              Appeal No. 2004-1823                                                                   Page 8                 
              Application No. 09/148,012                                                                                    

              alter lipoprotein, LDL, HDL or cholesterol levels in any mode, including altering SR-BI                       
              expression or binding of SR-BI to high density lipoprotein.                                                   
                     In considering this issue we note:                                                                     
                     [t]he question is not whether a claimed invention is an obvious variant of                             
                     that which is disclosed in the specification. Rather, a prior application itself                       
                     must describe an invention, and do so in sufficient detail that one skilled in                         
                     the art can clearly conclude that the inventor invented the claimed                                    
                     invention as of the filing date sought...It is not sufficient for purposes of the                      
                     written description requirement of Section 112 that the disclosure, when                               
                     combined with knowledge in the art, would lead one to speculate as to                                  
                     modifications that the inventor might have envisioned, but failed to                                   
                     disclose.                                                                                              
              Lockwood v. American Airlines Inc., 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966                                 
              (Fed. Cir. 1997).  At best, one may intuit or think it obvious that having generated                          
              infertile SR-BI knock out female mice, the effect may be reversible if SR-BI function is                      
              restored.  However, that is not the test.  Even it that was the test, claim 1 on appeal is                    
              not directed to methods involving affecting SR-BI function.  It is much broader in scope.                     

                     In response to the examiner’s rejections, appellant relies upon Miettinen.1                            
              Present appellant Monty Krieger is listed as a co-author in Miettinen.  We have                               
              considered Miettinen and find that it is not relevant since it was published in 2001, after                   
              the September 4, 1998, filing date of this application.  Furthermore, even if Miettinen is                    
              to be considered in determining the patentability of the claims, if anything, it supports                     
              our new ground of rejection since Miettinen states:                                                           
                     It is estimated that for 10-20% of women with infertility problems, the                                
                     underlying causes are unknown.  We are not aware of any reports                                        


                     1   Miettinen et al. (Miettinen), “Abnormal lipoprotein metabolism and reversible                      
              female infertility in HDL receptor (SR-BI)-deficient mice,” The Journal of Clinical                           
              Investigation, Vol. 108, No. 12, pp. 1717-1722 (2001)                                                         




Page:  Previous  1  2  3  4  5  6  7  8  9  10  11  12  Next 

Last modified: November 3, 2007